托珠单抗治疗巨细胞动脉炎的临床及生物学疗效：3例病例报告及文献综述
[Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review].
作者信息
Kieffer P, Hinschberger O, Ciobanu E, Jaeger-Bizet F, Drabo A, Mostoufizadeh T, Martzolff L
机构信息
Service de médecine interne, hôpital Emile-Muller, 20, rue du Dr-Laennec, 68100 Mulhouse, France.
Service de médecine interne, hôpital Emile-Muller, 20, rue du Dr-Laennec, 68100 Mulhouse, France.
出版信息
Rev Med Interne. 2014 Jan;35(1):56-9. doi: 10.1016/j.revmed.2012.12.012. Epub 2013 Sep 26.
INTRODUCTION
Treatment of giant cell arteritis is based on prolonged corticosteroid therapy but adverse side effects are common especially in the elderly.
CASE REPORTS
We report three patients with giant cell vasculitis treated by tocilizumab, an interleukin-6 receptor antibody, owing to resistance or intolerance to corticosteroid therapy. A favorable outcome was rapidly observed both on clinical and biological data allowing a corticoid therapy sparing.
CONCLUSION
Tocilizumab is a promising treatment of giant cell arteritis but controlled trials are needed to confirm its efficacy.
引言
巨细胞动脉炎的治疗基于长期使用皮质类固醇疗法，但不良反应很常见，尤其是在老年人中。
病例报告
我们报告了3例巨细胞血管炎患者，由于对皮质类固醇疗法耐药或不耐受，使用白细胞介素-6受体抗体托珠单抗进行治疗。在临床和生物学数据方面均迅速观察到良好结果，从而可以减少皮质类固醇疗法的使用。
结论
托珠单抗是一种有前景的巨细胞动脉炎治疗药物，但需要进行对照试验以证实其疗效。
Zotero 插件